The FDA on June 30, 2020 approved BAVENCIO® for maintenance treatment of patients with locally advanced or metastatic Urothelial Carcinoma (UC) that has not progressed with first-line Platinum-containing chemotherapy. BAVENCIO® is a product of EMD Serono, Inc.
Bottom Ad
Advertisement
Subscribe
